|
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Pathos Communications PLC - London-based public relations company - It wins the ‘largest contract in its history’. The client is a non-profit consulting firm, a ‘long-standing’ customer. The deal is worth $700,000 over 12-months, generating $500,000 in earnings before interest, tax, depreciation and amortisation across 2026 and 2027. ‘The engagement comprises a suite of Pathos’s premium multi-channel offerings, including television placements on leading US national business TV networks, podcasts, written articles and book publishing services. This demonstrates the company’s expanding product mix and reach, with these higher-value channels being increasingly key drivers of revenue diversification, deeper client engagement and margin progression,’ Pathos adds. ‘The revenue visibility from this contract also further underpins management confidence in achieving market expectations for FY2026.’ ---------- ProBiotix Health PLC - Wakefield, England-based life sciences firm - Reports a new strategic alliance in Spain and Portugal, worth €200,000 a year in ProBiotix sales. The deal is with Bioksan. The firm will supply its LPLDL probiotic strain to Bioksan. ‘Bioksan will use LPLDL as an anchor ingredient to replace red yeast rice which was previously being used within Lipok a leading cardiovascular health product, positioned within the pharmacy and nutraceutical market in Spain and Portugal,’ Probiotix adds. ‘Hitherto Monacolin K, a naturally occurring compound found in red yeast rice, has been used in cardiometabolic supplements to lower cholesterol.’ However, a probe by the European Food Standards Authority could lead to Monacolin K being prohibited. ‘If a ban takes place, more than 40 supplement brands in Europe currently using Monacolin K will require reformulation. These products represent an estimated consumer market value of €130 million per annum, creating a significant market opportunity for ProBiotix,’ the company adds. ---------- Tern PLC - London-based ’internet-of-things’ focused investor - Issued £270,000 worth of unsecured convertible loan notes by Talking Medicines Ltd, a service provider to healthcare advertising agencies. Talking Medicines uses AI technology to help its customers ‘consistently win and retain their Pharma clients’. The notes carry 10% annual interest and are convertible either on exit or a fundraising of at least £2 million by Talking Medicines. In both case, they will be converted at a 20% discount to the exit or fundraising price. ‘If neither an exit nor a relevant fundraising has taken place, the CLNs will mature on 21 November 2029, in line with the approximately £520,000 of convertible loan notes that the Company already holds in Talking Medicines,’ it adds. ---------- Georgina Energy PLC - onshore helium and hydrogen explorer with permits in Australia - It begins pre-drilling civil engineering site works for re-entry drilling at the Hussar prospect. ---------- Forgent PLC - London-based provider of syngas technology and engineering services for converting waste into sustainable energy and biofuels, and also has copper and gold assets - A programme of work has been submitted for a maiden drilling programme at Peak Hills in Western Australia. It eyes kicking off drilling in summer 2026. Three priority gold targets have been found following a review. ---------- Panther Metals PLC - Canada-focused mineral deposits exploration company - Begins a diamond drilling programme at the Awkward Conduit target at the Obonga asset in Ontario. ‘The initial phase of drilling will consist of a single near-vertical diamond drill hole to a planned depth of approximately 400 metres. The objective of the hole is to validate the company’s exploration theory and improve geological understanding of the target area,’ Panther Metals says. ---------- Velocity Composites PLC - Burnley, England-based supplier of composite material kits to aerospace and other high-performance manufacturers - Velocity Composites expects to report a decline in half-year earnings, but adds that it is trading in line with expectations. In the six months to April 30, revenue is expected to have declined to £8.4 million from £10.4 million a year prior. Adjusted earnings before interest, tax, depreciation and amortisation of £100,000 is expected, down from £300,000. The revenue decline is due to the ‘phasing of shipments’ to the second half. ‘Management’s full year revenue expectations remain unchanged as the phasing of shipments is weighted to the second half, reflecting the receipt of work from Velocity’s lead US customer and higher demand from legacy UK customers,’ Velocity adds. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
